<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 S36 IS: Protecting Our Youth from Dangerous Synthetic Drugs Act of 2015</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2015-01-06</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>114th CONGRESS</congress><session>1st Session</session><legis-num>S. 36</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20150106">January 6, 2015</action-date><action-desc><sponsor name-id="S221">Mrs. Feinstein</sponsor> (for herself, <cosponsor name-id="S324">Mrs. Shaheen</cosponsor>, <cosponsor name-id="S340">Ms. Ayotte</cosponsor>, <cosponsor name-id="S270">Mr. Schumer</cosponsor>, <cosponsor name-id="S341">Mr. Blumenthal</cosponsor>, <cosponsor name-id="S311">Ms. Klobuchar</cosponsor>, <cosponsor name-id="S223">Mrs. Boxer</cosponsor>, <cosponsor name-id="S349">Mr. Portman</cosponsor>, and <cosponsor name-id="S316">Mr. Whitehouse</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSJU00">Committee on the Judiciary</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To address the continued threat posed by dangerous synthetic drugs by amending the Controlled
			 Substances Act relating to controlled substance analogues.</official-title></form><legis-body><section id="S1" section-type="section-one"><enum>1.</enum><header>Short
			 title</header><text display-inline="no-display-inline">This Act may be cited as
			 the <quote><short-title>Protecting Our Youth from Dangerous Synthetic Drugs Act of 2015</short-title></quote>.</text></section><section id="id2008687D63C540DEB0E696A58A9274EC"><enum>2.</enum><header>Enforcement</header><subsection id="idC6D5B00BD4FA4C1C9695E21D268663A3"><enum>(a)</enum><header>In
			 general</header><text display-inline="yes-display-inline">The Controlled
			 Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/801">21 U.S.C. 801 et seq.</external-xref>) is amended—</text><paragraph id="id6070A89960754965B7F282986FFEF307"><enum>(1)</enum><text>in section
			 102(32), by striking subparagraph (A) and inserting the following:</text><quoted-block display-inline="no-display-inline" id="id2C61F76770744B8F9EC25D17CF2EFA42" style="OLC"><subparagraph id="id7D4F2F94B88246E7850ADB9F2D896A1B" indent="up1"><enum>(A)</enum><text>Except as provided in subparagraph
				(C), the term <term>controlled substance analogue</term> means—</text><clause id="idf797eedc4a244152823c7ed913ec5844"><enum>(i)</enum><text>a substance whose chemical
				structure is substantially similar to the chemical structure of a
			 controlled
				substance in schedule I or II—</text><subclause id="idf9841faaa1b4449fb0a326a948685607"><enum>(I)</enum><text>which has a stimulant, depressant, or
				hallucinogenic effect on the central nervous system that is
			 substantially
				similar to or greater than the stimulant, depressant, or
			 hallucinogenic effect
				on the central nervous system of a controlled substance in schedule
			 I or II;
				or</text></subclause><subclause id="idea562de49ca44e12b812df0c5c006f43"><enum>(II)</enum><text>with respect to a particular person,
				which such person represents or intends to have a stimulant,
			 depressant, or
				hallucinogenic effect on the central nervous system that is
			 substantially
				similar to or greater than the stimulant, depressant, or
			 hallucinogenic effect
				on the central nervous system of a controlled substance in schedule
			 I or II;
				or</text></subclause></clause><clause id="idC734FB73A297402E86508E1A8FF0E411"><enum>(ii)</enum><text>a substance designated as a
				controlled substance analogue by the Controlled Substance Analogue
			 Committee in
				accordance with section 201(i).</text></clause></subparagraph><after-quoted-block>;
				and</after-quoted-block></quoted-block></paragraph><paragraph id="id1D2055D80BD8433EB8F8CD57346A4176"><enum>(2)</enum><text>in section 201,
			 by adding at the end the following:</text><quoted-block display-inline="no-display-inline" id="id7B6AF1540A124392B0D33FA7AF212DDE" style="OLC"><subsection id="id60CF5AB3377F43EEAA7D39B7D8467108"><enum>(i)</enum><paragraph commented="no" display-inline="yes-display-inline" id="id908D960EC0D04866843BA45AFBD19D4C"><enum>(1)</enum><text>The Attorney General,
				in consultation with the Secretary of Health and Human Services,
			 shall
				establish an interagency committee, to be known as the Controlled
			 Substance
				Analogue Committee (referred to in this subsection as the
				<quote>Committee</quote>).</text></paragraph><paragraph id="idF9DBB534CAC6457988FBD7CF6C778182" indent="up1"><enum>(2)</enum><text>The Committee shall be—</text><subparagraph id="id7C3D94F6BB2043B7856DBAD9A712DCC5"><enum>(A)</enum><text>headed by the Administrator of the
				Drug Enforcement Administration; and</text></subparagraph><subparagraph id="id37453C3B7B554845A40E98AB13195BB4"><enum>(B)</enum><text>comprised of scientific experts in the
				fields of chemistry and pharmacology from—</text><clause id="id69F1DD4CE43B4A9E9D96F9F6304C9480"><enum>(i)</enum><text>the Drug Enforcement
				Administration;</text></clause><clause id="id7B5D5C1B8F7A40C79759E36B5F133F88"><enum>(ii)</enum><text>the National Institute on Drug
				Abuse;</text></clause><clause id="id2ACC7910DE75466C84973BABD1AFEDE7"><enum>(iii)</enum><text>the Centers for Disease Control
				and Prevention; and</text></clause><clause id="id783F7D4DB6584DCEBAC5D13F5D21A753"><enum>(iv)</enum><text>any other Federal agency
				determined by the Attorney General, in consultation with the
			 Secretary of
				Health and Human Services, to be appropriate.</text></clause></subparagraph></paragraph><paragraph id="id49483F5929534D5D9A71A88A7CB198E3" indent="up1"><enum>(3)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="id8B3379C9D38C4268A8D2180952B0BAC8"><enum>(A)</enum><text>The Committee shall
				convene, on an as needed basis, to establish and maintain a list of
			 controlled
				substance analogues.</text></subparagraph><subparagraph id="idA9EEC7AC3B484016A93E8EFAED132224" indent="up1"><enum>(B)</enum><text>A substance may be designated as a
				controlled substance analogue by the Committee under this
			 subsection if the
				substance is determined by the Committee to be similar to a
			 schedule I or II
				controlled substance in either its chemical structure or its
			 predictive effect
				on the body, in such a manner as to make it likely that the
			 substance will, or
				can be reasonably expected to have a potential for abuse.</text></subparagraph><subparagraph id="idA86F7E8D431B450FAB2D5B391350A864" indent="up1"><enum>(C)</enum><text>Evidence of human consumption by an
				individual or the public at large is not necessary before a
			 substance may be
				designated as a controlled substance analogue under this
			 subsection.</text></subparagraph><subparagraph id="idB9CE377AA1054503A7D4F2EF806A0EC8" indent="up1"><enum>(D)</enum><text>The Attorney General shall, through
				rulemaking, establish procedures of operation for the Committee.</text></subparagraph></paragraph><paragraph id="idAEDFE182C04E4847B7220D26B7554D49" indent="up1"><enum>(4)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="id834FE493F4BD4600BFC2636C4DA67DC8"><enum>(A)</enum><text>Not later than 30 days
				before each meeting of the Committee, the Attorney General shall
			 submit to the
				Secretary of Health and Human Services a notice of the meeting of
			 the
				Committee, which shall include—</text><clause id="id87457440C7C3456C86EC0A083ED61249" indent="up1"><enum>(i)</enum><text>a list of the substances to be
				considered by the Committee during the meeting for designation as a
			 controlled
				substance analogue; and</text></clause><clause id="id13B76B37763347808D7020478E68A147" indent="up1"><enum>(ii)</enum><text>a request for the Secretary of Health
				and Human Services to make a determination of whether an exemption
			 or approval
				for each substance listed under clause (i) is in effect under
			 section 505 of
				the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>).</text></clause></subparagraph><subparagraph id="id87ABA88FB00C421ABDE553CDD4941087" indent="up1"><enum>(B)</enum><text>Not later than 30 days after the date
				on which the Secretary of Health and Human Services receives notice
			 under
				subparagraph (A), the Secretary shall submit to the Attorney
			 General a written
				response to the request described under subparagraph (A)(ii). The
			 Committee
				shall consider the response submitted by the Secretary of Health
			 and Human
				Services in determining whether to designate a substance considered
			 by the
				Committee at the meeting as a controlled substance analogue.</text></subparagraph></paragraph><paragraph id="idA8073704B72A49C18B8F7853FA7686CA" indent="up1"><enum>(5)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="id57DF259EB1314BF999ECBEDE1FD0185E"><enum>(A)</enum><text>The Attorney General
				shall publish in the Federal Register any designation made by the
			 Committee
				under this subsection.</text></subparagraph><subparagraph id="id6B4D22FCBB12484E8A116CD4B3236ED8" indent="up1"><enum>(B)</enum><text>The Administrator of the Drug
				Enforcement Administration shall publish, on the website of the
			 Drug
				Enforcement Administration, a description of each designation made
			 by the
				Committee under this subsection, which shall include—</text><clause id="id8405A18A419B4061B678D6120ACCEF18"><enum>(i)</enum><text>the chemical and common name of the
				controlled substance analogue;</text></clause><clause id="idF904CB65FDDB4A95A2A3D0595D377E38"><enum>(ii)</enum><text>the effective date of the
				determination, as described in paragraph (6)(A); and</text></clause><clause id="id0F42916BE9644882B6DFE9CE1F35257C"><enum>(iii)</enum><text>any schedule I or II controlled
				substance that the Committee has determined a substance is an
			 analogue
				of.</text></clause></subparagraph></paragraph><paragraph id="idA06C8D818F6A43CF91BFA245B5AB1BA5" indent="up1"><enum>(6)</enum><text>A designation made by the Committee
				under this subsection shall take effect on the date that is 30 days
			 after the
				date on which the designation is published in the Federal Register
			 under
				paragraph (5)(A).</text></paragraph><paragraph id="idE4C9408110154D5B94DABED3DD12EEE3" indent="up1"><enum>(7)</enum><text>If a substance designated as a
				controlled substance analogue by the Committee under this section
			 is
				subsequently scheduled through a rulemaking proceeding under
			 subsection (a),
				(d), or (h), the substance shall be automatically removed from the
			 controlled
				substance analogue list.</text></paragraph><paragraph id="idF8B183CE1D244102B58B4704896981A8" indent="up1"><enum>(8)</enum><text>If a defendant challenges the
				designation of a controlled substance analogue made by the
			 Committee under this
				subsection the issue shall be considered a question of
				law.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="id2F8305E0FC9F4EB6BD03E5AE39CDED93"><enum>(b)</enum><header>Funding</header><text>Section
			 111(b)(2)(B) of <external-xref legal-doc="public-law" parsable-cite="pl/102/395">Public Law 102–395</external-xref> (<external-xref legal-doc="usc" parsable-cite="usc/21/886a">21 U.S.C. 886a(2)(B)</external-xref>) is amended by
			 inserting <quote>controlled substance analogues,</quote> after
			 <quote>substances,</quote>.</text></subsection></section><section id="id19FBADED53A04E67983F0B36F1D8DDBF"><enum>3.</enum><header>Importation of
			 controlled substance analogues</header><text display-inline="no-display-inline">Section 1002 of the Controlled Substances
			 Import and Export Act (<external-xref legal-doc="usc" parsable-cite="usc/21/952">21 U.S.C. 952</external-xref>) is amended—</text><paragraph id="id6E7D2014487A4E858B46EEE686FB3D9E"><enum>(1)</enum><text>by redesignating
			 subsections (c) through (e) as subsections (d) through (f), respectively;
			 and</text></paragraph><paragraph id="idA50648C2207F4DD9960B77B1559272EB"><enum>(2)</enum><text>by inserting
			 after subsection (b) the following:</text><quoted-block display-inline="no-display-inline" id="id0B4C051427E640B78CE83A89D83E8785" style="OLC"><subsection id="id3140211C4EB94886B5545955453D3892"><enum>(c)</enum><text>It shall be
				unlawful to import into the customs territory of the United States
			 from any
				place outside thereof (but within the United States), or to import
			 into the
				United States from any place outside thereof, any controlled
			 substance analogue
				designated pursuant to section 201(i) of the Controlled Substances
			 Act (21
				U.S.C. 811(i)) unless the controlled substance analogue is imported
			 pursuant to
				such notification or declaration as the Attorney General may by
			 regulation
				prescribe.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section><section id="id0051B7FD54E34DB2A2FF16422F4B778B"><enum>4.</enum><header>Directive to
			 Sentencing Commission</header><subsection id="id6417b965150f414aa84a26bef1855cce"><enum>(a)</enum><header>In
			 general</header><text>Pursuant to its authority under <external-xref legal-doc="usc" parsable-cite="usc/28/994">section 994</external-xref> of title 28,
			 United States Code, the United States Sentencing Commission shall review
			 and,
			 if appropriate, amend the Federal sentencing guidelines and policy
			 statements
			 to ensure the guidelines and policy statements provide adequate penalties
			 for
			 any offense involving the unlawful manufacturing, importing, exporting, or
			 trafficking of controlled substance analogues under part D of the
			 Controlled
			 Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/841">21 U.S.C. 841 et seq.</external-xref>) or part A of the Controlled
			 Substances
			 Import and Export Act (<external-xref legal-doc="usc" parsable-cite="usc/21/951">21 U.S.C. 951 et seq.</external-xref>) and similar offenses,
			 including
			 unlawful possession, possession with intent to commit any of the foregoing
			 offenses, and attempt and conspiracy to commit any of the foregoing
			 offenses.</text></subsection><subsection id="id140980dd568344f19ebf490454814ff7"><enum>(b)</enum><header>Commission
			 duties</header><text>In carrying out this section, the Sentencing Commission
			 shall—</text><paragraph id="id971e86a1c9a1490c94113f95c210c410"><enum>(1)</enum><text>ensure that the
			 sentences, guidelines, and policy statements relating to offenders
			 convicted of
			 these offenses are appropriately severe and reasonably consistent with
			 other
			 relevant directives and other Federal sentencing guidelines and policy
			 statements;</text></paragraph><paragraph id="id53409e810ce8433f991cbe1950be73d0"><enum>(2)</enum><text>make any
			 necessary conforming changes to the Federal sentencing guidelines; and</text></paragraph><paragraph id="id6564fda7336f4697a4b6b2f3992f019f"><enum>(3)</enum><text>assure that the
			 guidelines adequately meet the purposes of sentencing as set forth in
			 section
			 3553(a)(2) of title 18, United States Code.</text></paragraph></subsection></section></legis-body></bill>


